A pandemic is not inevitable, scientists say. But the outbreak has passed worrisome milestones in recent weeks, including ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and ... Moderna plans to advance ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of the oral influenza polymerase basic 2 (PB2) inhibitor, CC-42344, following unpredictable ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight ...

Moderna gets a $590 million federal boost to continue work on development of a vaccine to protect against bird flu.

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

The robust safety database of the LUNAR and STARR technologies have been established through multiple COVID-19 and seasonal influenza vaccine trials, which included more than 20,000 participants ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

s Phase 1 study of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The ...